It has been determined that PI3K/AKT mutations have a significant role in cell survival, proliferation, and angiogenesis in ovarian cancer; as a result, therapeutic targeting with PI3K/AKT inhibitors and mTOR inhibitors has been studied [57]. Here, AKT1 is linked to ovarian carcinoma.